To hear about similar clinical trials, please enter your email below
Trial Title:
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
NCT ID:
NCT05923879
Condition:
Lymphoma, Large B-Cell, Diffuse
Conditions: Official terms:
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Rituximab
Lenalidomide
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Drug
Intervention name:
Selinexor combined with lenalidomide and rituximab
Description:
Selinexor combined with lenalidomide and rituximab
Summary:
This is a retrospective observational study of the therapeutic mechanism and resistance
mechanism of the treatment of Selinexor combined with lenalidomide and rituximab in
diffuse large B-cell lymphoma patients. By detecting the immune cells in peripheral blood
and tumor tissues of patients before and after treatment, the key immune cell subsets and
immune molecules linked to the action and resistance of the treatment of Selinexor
combined with lenalidomide and rituximab, so as to provide the basis for the optimization
of the treatment or the combination of other immunotherapies.
Criteria for eligibility:
Study pop:
Over 18-year-old recurrent or refractory diffuse large B-cell lymphoma patients receiving
Selinexor combined with lenalidomide and rituximab would be enrolled.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. At least 18 years old.
2. Histopathologically confirmed diffuse large B-cell lymphoma according to World
Health Organization (WHO) classification criteria 2016.
3. There is evidence of relapsed or refractory disease.
4. Treatment with Selinexor combined with lenalidomide and rituximab.
Exclusion Criteria:
- No
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Address:
City:
Shanghai
Country:
China
Contact:
Last name:
Weili Zhao
Email:
zwl_trial@163.com
Start date:
June 30, 2023
Completion date:
June 30, 2025
Lead sponsor:
Agency:
Ruijin Hospital
Agency class:
Other
Source:
Ruijin Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05923879
